Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02407041 · ClinicalTrials.gov registry record · Phase 2
An Open-Label, Phase 2a Study to Evaluate Safety and Efficacy of GR-MD-02 for Treatment of Psoriasis
A Phase 2 study, sponsored by Galectin Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT02407041: Completed Phase 2 study, sponsored by Galectin Therapeutics.
NCT02407041 is a Phase 2 study that has completed, run by Galectin Therapeutics. The registered enrollment target is 5 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02407041, a Phase 2 study, has completed, sponsored by Galectin Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
Study GT-030 is a phase 2a, single-center, open-label study of subjects with moderate to severe plaque psoriasis
Primary Outcome
The primary endpoint will be the number of participants with PASI-75, or a 75% improvement from baseline (day 1, prior to first infusion) in PASI score as assessed at the 30 day follow up visit.
Interventions
- DRUG GR-MD-02
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2015-09 |
| Est. Completion | 2018-03 |
| Phase | Phase 2 |
What the finished NCT02407041 record still lists
NCT02407041 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 1 intervention - of which GR-MD-02 is the first listed.
NCT02407041 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02407041 about?
NCT02407041 is a clinical study titled "An Open-Label, Phase 2a Study to Evaluate Safety and Efficacy of GR-MD-02 for Treatment of Psoriasis". Study GT-030 is a phase 2a, single-center, open-label study of subjects with moderate to severe plaque psoriasis
What is the current status of trial NCT02407041?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2015-09. Estimated completion is 2018-03.
What interventions are being tested in trial NCT02407041?
The interventions under investigation include: GR-MD-02 (DRUG).
Who is sponsoring clinical trial NCT02407041?
This trial is sponsored by Galectin Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02407041's enrollment target sits among peer trials
5 2000th of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia